Streamlining Change Healthcare Prior Authorization for Pulmonology
Navigating Change Healthcare prior authorization for pulmonology services requires precision and up-to-date clinical understanding to ensure timely patient access to critical therapies.
Revenue cycle leaders and prior authorization teams face significant administrative burdens managing complex PA requirements. For pulmonology, this includes high-cost biologics, durable medical equipment, and advanced therapies, often subject to stringent medical necessity criteria. Klivira integrates directly to streamline these workflows, enhancing efficiency for Change Healthcare prior authorization for pulmonology.
Understanding Change Healthcare's PA Landscape for Pulmonology
Change Healthcare, as a key player in healthcare technology and services, processes a vast array of prior authorization requests. For pulmonology practices, this necessitates a clear understanding of Change Healthcare's specific submission channels, documentation requirements, and policy interpretations, which can vary based on the benefit plan design. Efficiently managing these interactions is crucial for maintaining patient care continuity and optimizing revenue.
Common Pulmonology Services Requiring Prior Authorization from Change Healthcare
- Asthma biologics: omalizumab (Xolair), mepolizumab (Nucala), reslizumab (Cinqair), benralizumab (Fasenra), dupilumab (Dupixent), tezepelumab (Tezspire)
- Home oxygen and durable medical equipment (e.g., BiPAP/CPAP)
- IPF (idiopathic pulmonary fibrosis) antifibrotics: pirfenidone (Esbriet), nintedanib (Ofev)
- Advanced COPD specialty drugs like ensifentrine (Ohtuvayre) and certain triple-therapy inhalers (Trelegy, Breztri)
- Lung transplant evaluation and associated immunosuppression therapies
- Pulmonary function testing and other high-cost diagnostic procedures
Navigating Change Healthcare's Medical Necessity Criteria and Documentation
Change Healthcare's prior authorization decisions for pulmonology services are driven by proprietary medical necessity criteria, often referencing widely accepted clinical guidelines such as those from ATS, GOLD for COPD, and GINA for asthma. Submitting comprehensive documentation, including eosinophil counts, detailed exacerbation history, and proof of prior controller therapy at maximum dose, is paramount to meeting these stringent requirements, especially for biologics.
Common Denial Themes in Change Healthcare Pulmonology Prior Authorizations
Pulmonology prior authorizations submitted through Change Healthcare are frequently denied for specific reasons. Common issues include failure to meet step-therapy requirements for asthma biologics, where a trial of high-dose ICS-LABA may be mandated. Denials also occur when eosinophil-count thresholds are not met for IL-5-targeting biologics or when conservative therapies are deemed insufficient for conditions like IPF, highlighting the need for precise documentation and adherence to payer policy.
Optimizing Change Healthcare PA Workflows with Klivira
Klivira's platform automates the complex prior authorization process, directly integrating with EMRs to streamline submissions to Change Healthcare. Our system incorporates GINA/GOLD/ATS-aware step-therapy logic and facilitates automated documentation of critical data points like eosinophil counts. This approach not only accelerates initial approvals but also simplifies asthma biologic re-authorization workflows, reducing administrative burden and improving turnaround times.
Change Healthcare's Network Design and PA Impact
The network design (e.g., HMO, PPO, EPO) of health plans utilizing Change Healthcare's services significantly influences prior authorization workflows for pulmonology. HMO plans typically require primary care physician referrals and strict adherence to in-network providers, impacting PA routing. Understanding these network distinctions and how they interface with Change Healthcare's PA submission portals is critical for avoiding delays and ensuring proper claim processing.
Frequently asked questions
What pulmonology services commonly require prior authorization from Change Healthcare?
Change Healthcare typically requires prior authorization for high-cost pulmonology services such as asthma biologics (e.g., Dupixent, Nucala), home oxygen, BiPAP/CPAP equipment, IPF antifibrotics (e.g., Ofev), and lung transplant evaluations. These services often involve complex medical necessity reviews due to their cost and specialized nature.
How do Change Healthcare's medical necessity criteria impact asthma biologic approvals?
Change Healthcare's medical necessity criteria for asthma biologics often align with clinical guidelines like GINA, requiring specific eosinophil counts, documentation of prior controller therapy at maximum dose, and a history of exacerbations. Failure to meet these precise thresholds or demonstrate step-therapy compliance is a common reason for denial.
What documentation is critical for Change Healthcare prior authorizations for IPF antifibrotics?
For IPF antifibrotics like pirfenidone and nintedanib, Change Healthcare prior authorizations necessitate comprehensive documentation of a confirmed IPF diagnosis, evidence of disease progression, and often a trial or contraindication to conservative therapies. Detailed pulmonary function test results and clinical notes are crucial for approval.
How does Klivira automate Change Healthcare PA submissions for pulmonology?
Klivira automates Change Healthcare PA submissions for pulmonology by integrating directly with your EMR to extract relevant patient data. Our platform then applies intelligent logic based on GINA/GOLD/ATS guidelines to pre-populate forms, identify missing documentation, and submit the PA request electronically, streamlining the entire workflow.
What are common reasons for Change Healthcare prior authorization denials in pulmonology?
Common Change Healthcare prior authorization denials in pulmonology stem from non-adherence to step-therapy protocols for biologics, insufficient eosinophil counts for IL-5 inhibitors, or inadequate documentation of prior conservative treatments for conditions like IPF. Incomplete clinical notes or lack of supporting diagnostic evidence also frequently lead to denials.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo